Search Result

Isoforms Recommended:	Cleavable Linker

Results for "

Cleavable,linker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Linker (34) ADC Payload (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (13) Apoptosis (3) Bacterial (1) Biochemical Assay Reagents (2) c-Met/HGFR (1) DNA/RNA Synthesis (1) Drug-Linker Conjugates for ADC (23) EGFR (3) FGFR (1) Interleukin Related (1) Microtubule/Tubulin (5) N-myristoyltransferase (1) Notch (1) PARP (1) TAM Receptor (1) Toll-like Receptor (TLR) (1) Topoisomerase (6)
By Research Areas:	Cancer (72) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (2)
Click Chemistry:	ADC Synthesis (3) DBCO (3) Azide (2)
Oligonucleotides:	Nucleoside Phosphoramidites (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145735

Allyl (2-aminoethyl)carbamate	ADC Linker	Others
Allyl (2-aminoethyl)carbamate is a cleavable linker.

HY-W098764

Allyl (2-aminoethyl)carbamate hydrochloride	ADC Linker	Others
Allyl (2-aminoethyl)carbamate hydrochloride is a cleavable linker.

HY-129365

SNPB	ADC Linker	Cancer
SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-126498

PDEC-NB	ADC Linker	Cancer
PDEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).

HY-44235

MC-Gly-Gly-Phe	ADC Linker	Cancer
MC-Gly-Gly-Phe is a cleavable linker used for antibody-drug conjugates (ADC).

HY-126530

PPC-NB	ADC Linker	Cardiovascular Disease Cancer
PPC-NB is a glutathione cleavable linker used for the antibody-drug conjugate (ADC) .

HY-129376

Sulfo-SNPB	ADC Linker	Cancer
Sulfo-SNPB is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-126519

PDdEC-NB	ADC Linker	Cancer
PDdEC-NB is a disulfide cleavable linker used for the antibody-drug conjugate (ADC).

HY-129375

SNPB-sulfo-Me	ADC Linker	Cancer
SNPB-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-19318A

Fmoc-Val-D-Cit-PAB	ADC Linker	Cancer
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .

HY-19318B

Fmoc-D-Val-Cit-PAB	ADC Linker	Cancer
Fmoc-D-Val-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .

HY-153180

PB038	Drug-Linker Conjugates for ADC	Cancer
PB038 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan .

HY-153947

PB089	Drug-Linker Conjugates for ADC	Cancer
PB089 is a Drug-liker containing a PEG unit and a cleavable linker attached to Exatecan .

HY-129367

NO2-SPP	ADC Linker	Cancer
NO2-SPP is a cleavable linker that is used for making antibody-drug conjugate (ADC).

HY-129353

Boc-Phe-(Alloc)Lys-PAB-PNP	ADC Linker	Cancer
Boc-Phe-(Alloc)Lys-PAB-PNP is a used as a cleavable linker for antibody-drug conjugates (ADC).

HY-128929

Fmoc-PEA	ADC Linker	Cancer
Fmoc-PEA (Example 1-2) is a used as a cleavable linker for antibody-drug conjugates (ADC) .

HY-129352

Cbz-Phe-(Alloc)Lys-PAB-PNP	ADC Linker	Cancer
Cbz-Phe-(Alloc)Lys-PAB-PNP is an cleavable linker for antibody-drug conjugates (ADC) design.

HY-19318C

Fmoc-D-Val-D-Cit-PAB	ADC Linker	Cancer
Fmoc-D-Val-D-Cit-PAB is a cleavable linker for antibody-agent-conjugation (ADC) .

HY-44235A

MC-Gly-Gly-D-Phe	ADC Linker	Cancer
MC-Gly-Gly-D-Phe is a cleavable linker used for sythesis of antibody-drug conjugates (ADC).

HY-400191A

Fmoc-Gly-Gly-allyl propionate	ADC Linker	Cancer
Fmoc-Gly-Gly-allyl propionate is a cleavable linker that can be used to synthesize Antibody-Drug Conjugates (ADCs) .

HY-128940

EC089	ADC Linker	Cancer
EC089 is a cleavable linker used in conjugates of tubulysins and folates, and extracted from patent WO2011069116A1 .

HY-400191

Fmoc-Gly-(d-Gly)-allyl propionate	ADC Linker	Cancer
Fmoc-Gly-(d-Gly)-allyl propionate is a cleavable linker that can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-129378

NO2-SPP-sulfo-Me	ADC Linker	Cancer
NO2-SPP-sulfo-Me is a cleavable linker that is used for making antibody-drug conjugate (ADC) .

HY-W011561

Boc-NH-C6-Br	ADC Linker	Cancer
Boc-NH-C6-Br is a non-cleavable linker used for antibody-drug conjugates (ADC) .

HY-400356

Glucocorticoid receptor agonist-1 phosphate Gly-Glu TFA	ADC Linker	Cancer
Glucocorticoid receptor agonist-1 phosphate Gly-Glu (TFA) is a cleavable linker, that can be used to synthesize Antibody-Drug Conjugates (ADCs).

HY-44980

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-141153

Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP	ADC Linker	Cancer
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP is a cleavable linker for synthesis of antibody-drug conjugates (ADCs) .

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-101162

SGD-1910	Drug-Linker Conjugates for ADC	Cancer
SGD-1910 is a *agent-linker* conjugate for ADC** by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala .

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-128954

Sulfo-PDBA-DM4	Drug-Linker Conjugates for ADC	Inflammation/Immunology Cancer
Sulfo-PDBA-DM4 is a *agent-linker* conjugate** composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker.

HY-173079

TLR7 agonist 30	Toll-like Receptor (TLR) Drug-Linker Conjugates for ADC	Cancer
TLR7 agonist 30 (compound 2) is an agent-linker conjugate for ADC. TLR7 agonist 30 contains a TLR7 agonist (compound 1) and a cleavable linker, and has potent anti-tumor activity .

HY-20336

Mc-Val-Cit-PABC-PNP 4 Publications Verification Maleimidocaproyl-L-valine-L-citrulline-p-aminobenzyl alcohol p-nitrophenyl carbonate	ADC Linker	Others Inflammation/Immunology Cancer
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable linker for antibody-drug conjugates (ADCs) which couples the antibody element to the effecting compound. Mc-Val-Cit-PABC-PNP can be used in the synthesis of ADCs .

HY-126681

SC-VC-PAB-MMAE 2 Publications Verification NHS-VC-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
SC-VC-PAB-MMAE is a *agent-linker* conjugate for ADC** with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB .

HY-41189

Fmoc-Val-Cit-PAB-PNP	ADC Linker	Cancer
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .

HY-W190907

Trifluoroacetamidoethyl-SS-propionic NHS ester	Biochemical Assay Reagents	Others
Trifluoroacetamidoethyl-SS-propionic NHS ester is a cleavable linker containing an NHS ester. The NHS ester can be used to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules. The disulfide bond can be cleaved under reduction conditions.

HY-111554

AcLys-PABC-VC-Aur0101	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
AcLys-PABC-VC-Aur0101 is a *agent-linker* conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the cleavable linker AcLys-PABC-VC .

HY-174447

ADP-ribose/PARP-IN-1	PARP	Cancer
ADP-ribose/PARP-IN-1 (Compound Ex.16) is a conjugated compound. ADP-ribose/PARP-IN-1 contains disease targeting moieties, PARP inhibitor moieties, cleavable linkers, chelators. ADP-ribose/PARP-IN-1 targets specific targets through the disease targeting moiety and selectively delivers PARP inhibitors to tumor cells. The cleavable linker of ADP-ribose/PARP-IN-1 releases the PARP inhibitor under appropriate conditions, inhibiting PARP to prevent DNA damage repair, while the radionuclide carried by the chelator exerts a killing effect. ADP-ribose/PARP-IN-1 can be used in the research of prostate cancer .

HY-171931

Aminocaproyl-Val-Cit-PABC-Exatecan	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan is a *drug-linker* conjugate for ADC*, consiting of a cleavable linker* (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis .

HY-W071967

Alloc-Val-Ala-pAB	ADC Linker	Cancer
Alloc-Val-Ala-PAB is a peptide cleavable linker used in the synthesis of antibody-drug conjugates (ADCs). The Val-Ala will specifically be cleaved by Cathepsin B. The Alloc group is stable to treatment with piperidine and TFA, but can be easily removed under mild conditions by palladium catalyzed allyl transfer.

HY-145674

HDP 30.1699	DNA/RNA Synthesis ADC Payload	Cancer
HDP 30.1699, the derivative of α-Amanitin, shows considerable cross-links. The cysteine residues of the anti-HER2 THIOMAB antibody are used for conjugation of the cysteine reactive linker–Amanitin compound, HDP 30.1699, with a cleavable linker by maleimide chemistry .

HY-171931A

Aminocaproyl-Val-Cit-PABC-Exatecan TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a *drug-linker* conjugate for ADC*, consiting of a cleavable linker* (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis .

HY-126350

CL2-SN-38 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
CL2-SN-38 is a cleavable linker-based *agent-Linker* conjugate**, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .

HY-151944

Antibacterial agent 128	Bacterial Antibiotic	Infection
Antibacterial agent 128 is a siderophore analog-Ciprofloxacin (Ciprofloxacin (HY-B0356)) conjugate with a cleavable linker. Antibacterial agent 128 shows antibiotic activities against *P. aeruginosa* (MIC values of 0.25-64 μg/mL) and *B. pseudomallei* (MIC values of 1-32 μg/mL) .

HY-W109224

3,3'-(Propane-2,2-diylbis(sulfanediyl))dipropionic acid	ADC Linker	Cancer
3,3'-(Propane-2, 2-Diylbis (sulfanediyl))dipropionic acid is a ROS-sensitive cleavable linker that can be used in the synthesis of ADCs. 3,3'-(Propane-2,2-diylbis(sulfanediyl))dipropionic acid is promising for research of tumor drug delivery systems .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-W190951

3-((2-(2,2,2-Trifluoroacetamido)ethyl)disulfanyl)propanoic acid	Biochemical Assay Reagents	Others
3-((2-(2,2,2-Trifluoroacetamido)ethyl)disulfanyl)propanoic acid is a cleavable linker containing a carboxylic acid. The terminal carboxylic acid can be reacted with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. The disulfide bond can be cleaved via reduction reactions.

HY-44980G

Fmoc-Gly-NH-CH2-acetyloxy	ADC Linker	Cancer
Fmoc-Gly-NH-CH2-acetyloxy GMP is a GMP grade Fmoc-Gly-NH-CH2-acetyloxy (HY-44980). Fmoc-Gly-NH-CH2-acetyloxy is a cleavable linker that can be used to synthesize antiboy-drug Conjugates (ADCs).

HY-111555

AmPEG6C2-Aur0131	Microtubule/Tubulin Drug-Linker Conjugates for ADC	Cancer
AmPEG6C2-Aur0131 is a *agent-linker* conjugate for ADC** (anti-CXCR4 ADC) with potent antitumor activity by using Aur0131 (an auristatin microtubule inhibitor), linked via the non-cleavable linker AmPEG6C2 .

Cat. No.	Product Name	Target	Research Area

HY-P1449

Boc-Gly-Gly-Phe-Gly-OH	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P1449A

Boc-Gly-Gly-Phe-Gly-OH TFA	ADC Linker	Cancer
Boc-Gly-Gly-Phe-Gly-OH TFA, a self-assembly of N- and C-protected tetrapeptide, is a protease cleavable linker used for the antibody-drug conjugate (ADC).

HY-P4139

activable cell-penetrating peptide (ACCP)	Peptides	Others
activable cell-penetrating peptide (ACCP) consists of a polycationic CPP (typically arg9 or r9) connected via a cleavable linker to a matching polyanion (typically glu9 or e9), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells .

Cat. No.	Product Name	Target	Research Area

HY-P99593

Sofituzumab vedotin DMUC5754A	Antibody-Drug Conjugates (ADCs)	Cancer
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer .

HY-P9988

Mecbotamab BA301	ADC Antibody TAM Receptor	Cancer
Mecbotamab is a humanized IgG1-κ antibody targeting to AXL receptor tyrosine kinase (AXL). Mecbotamab can serves as a conditionally active biologic (CAB), which can be conjugated with MMAE (HY-15162) via a cleavable linker, to form ADC Mecbotamab vedotin (BA3011) .

HY-P99813

Patritumab deruxtecan HER3-DXd; U3-1402	Antibody-Drug Conjugates (ADCs)	Cancer
Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity .

HY-P99542

Tusamitamab ravtansine SAR-408701; HuMAb2-3-SPDB-DM4	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 (HY-12454), via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.8 .

HY-P99101

Vobramitamab AEX-4089	ADC Antibody	Cancer
Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma .

HY-P99683

Ladiratuzumab vedotin SGN-LIV1A	Antibody-Drug Conjugates (ADCs)	Cancer
Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC₅₀: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer .

HY-141600

Aprutumab ixadotin BAY 1187982	Antibody-Drug Conjugates (ADCs) FGFR Microtubule/Tubulin Apoptosis	Cancer
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .

HY-P99595

Sirtratumab vedotin AGS15E; ASG-15ME; 1vcMMAE	Antibody-Drug Conjugates (ADCs)	Cancer
Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker .

HY-141599

Camidanlumab tesirine ADCT 301	Antibody-Drug Conjugates (ADCs) Interleukin Related	Cancer
Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines .

Cat. No.	Product Name		Classification

HY-115524

DBCO-NHS ester 2		ADC Synthesis DBCO
DBCO-NHS ester 2 is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 2 is a derivative of Dibenzylcyclooctyne (DBCO) used in copper-free click chemistry[1]. DBCO-NHS ester 2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-133492

DBCO-PEG4-MMAF		DBCO ADC Synthesis
DBCO-PEG4-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the tubulin polymerization inhibitor, MMAF, linked via the cleavable linker DBCO-PEG4. DBCO-PEG4-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-115545

DBCO-NHS ester 3		ADC Synthesis DBCO
DBCO-NHS ester 3 (Compound 12) is a cleavable linker that is used for making antibody-drug conjugate (ADC). DBCO-NHS ester 3 is a derivative of Dibenzylcyclooctyne (DBCO) obtained by activation of N-hydroxysuccinimide by the carboxylic acid moiety of both methyl-oxanorbornadiene (MeOND) and dibenzoazacyclooctyne (DIBAC) . DBCO-NHS ester 3 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-W190943

Azido-PEG4-Val-Cit-PAB-MMAE 1 Publications Verification		Azide
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-131088

N3-PEG8-Phe-Lys-PABC-Gefitinib		Azide
N3-PEG8-Phe-Lys-PABC-Gefitinib is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-tumor agent, Gefitinib (orally active EGFR tyrosine kinase inhibitor), linked via the cleavable linker N3-PEG8-Phe-Lys-PABC. N3-PEG8-Phe-Lys-PABC-Gefitinib is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: